More jobs! CARB-X also has openings

Dear All:

Building on my recent note about a search for the G20 secretariat lead, we now have CARB-X getting into job creation mode by posting 8 positions across 5 different job openings:

  • Accelerator Lead: coordinates the work of the growing accelerator network for all CARB-X-funded companies.
  • Support Team Lead (three positions): takes responsibility for managing the full range of support capabilities for 10-15 biotech and pharma companies in the Powered by CARB-X portfolio.
  • Director of Finance and Compliance: coordinates multiple partners and sub-grant recipients to ensure financial operations are in line with plans, plays a critical role in budget forecasting and planning processes, and more.
  • Project Manager: plays a critical role in the planning and execution of the funding cycles and coordination of pre-award and post-award activities.
  • Cycle Lead (two positions): takes full ownership of $20-50M funding Cycles from the preparatory stages through the three step application process, leading to the selection of a dozen or more additional companies for milestone-based awards.

As you hopefully already know, CARB-X began mid-2016 to award more than $455 million for research over a five-year period. I recently wrote about their search for new accelerators and it is good to see this continued expansion of their team. As one of the largest public-private research partnerships in the world. CARB-X is building an extraordinary pipeline of AMR-focused projects. If one of these opportunities intrigues, please check out the complete job postings online.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Scroll to Top